BACKGROUND: In the prostate-specific antigen era, potentially indolent prostate tumors are radically treated, causing overtreatment.
Molecular prognostic factors might differentiate indolent from aggressive tumors, allowing avoidance of unnecessary treatment.
PATIENTS AND METHODS: Fifty-two prostate cancer patients (20 organ-confined and 32 metastatic) were selected. All formalin-fixed and paraffin-embedded primary biopsies and matched metastases of 15 of them were evaluated for tumor and endothelial cell Id1 protein expression. Seventy-nine additional patients with organ-confined prostate cancer were selected for Id1 mRNA in silico analysis.
RESULTS: Among metastatic cancer subjects, 48% of primary tumors and 38% of metastases showed Id1 tumor cell expression, and 79% of primary tumors and 81% of metastases showed endothelial immunoreactivity. In the organ-confined group none of them showed Id1 protein tumor cell expression and 50% displayed endothelial expression. In the metastatic patients group, lower levels of Id1 protein predicted a nonsignificant longer overall survival (13 months vs. 7 months; P = .79). In the in silico analysis, however, lower levels of Id1 mRNA predicted a longer disease-free survival (61 months vs. not-reached; P = .018) and the hazard ratio for progression was 0.451 (P = .022) in favor of patients showing lower levels.
CONCLUSION: In our cohort, it seems to be a differential epithelial expression of Id1 protein according to the prognostic features (metastatic/poor prognosis vs. organ-confined/good prognosis). In localized tumors treated with radical prostatectomy, higher Id1 mRNA expression levels might predict a higher hazard ratio for progression and a shorter disease-free survival. Further validation of these results in larger prospective series is warranted.
Written by:
Ponz-Sarvisé M, Castañón E, Panizo-Santos A, Redrado M, López I, Rosell D, Gil-Aldea I, Calvo A, Nguewa PA, Gil-Bazo I. Are you the author?
Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Division of Oncology, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Reference: Clin Genitourin Cancer. 2013 Oct 12. pii: S1558-7673(13)00210-3.
doi: 10.1016/j.clgc.2013.08.007
PubMed Abstract
PMID: 24129125
UroToday.com Prostate Cancer Section
